KRT18 and metabolic dysfunction-associated steatotic liver disease: Recently, assessment of hepatocyte apoptosis by quantification of soluble cytokeratin 18 (CK-18) has been validated in large cohorts of NAFLD patients as a novel biomarker of disease activity [9].